MRI fusion prostate biopsy targets suspicious MRI lesions instead of relying only on blind sampling.
MRI fusion biopsy combines prostate MRI findings with real-time ultrasound guidance to target suspicious lesions. It is commonly paired with systematic samples because targeted and systematic biopsy answer different parts of the cancer-detection question.
Who this may fit
- Men with suspicious MRI lesions after elevated PSA or abnormal exam.
- Patients with prior negative biopsy but continued concern.
- Men deciding between transperineal and transrectal biopsy routes.
Evaluation before treatment
MRI report, actual images, PSA density, anticoagulants, infection history, and anesthesia plan should be reviewed.
The route and sampling plan are selected based on lesion location, risk profile, and physician judgment.
Recovery and follow-up
Temporary blood in urine, semen, or stool can occur, depending on biopsy route.
Fever, chills, inability to urinate, or worsening symptoms after biopsy require urgent contact.
Common questions
Does MRI fusion biopsy guarantee cancer detection?
No. It improves targeting of suspicious areas, but pathology depends on sampled tissue and cancer location.
Are systematic samples still needed?
Often yes. Many biopsy plans include targeted and systematic samples to reduce missed disease.
Related patient guides
Sources